DOLBY MEDICAL HOME RESPIRATORY CARE LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. DOLBY MEDICAL HOME RESPIRATORY CARE LIMITED 2010-08-09 → present
2. DOLBY MEDICAL LIMITED 2008-08-11 → 2010-08-09
3. R.L. DOLBY & COMPANY LIMITED 1978-01-18 → 2008-08-11

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

James Cowper Kreston Audit

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors expect the company to continue to generate positive cash flows on its own account for the foreseeable future. The successful granting of 5-year extensions to our three England 10-year service contracts in October 2025 has secured our primary revenue base through 2030. Furthermore, the strategic expansion into new service lines, highlighted by the award of a new Sleep Service contract in 2025 and the successfül launch of an additional contract in February 2026, provides a clear trajectory for continued organic growth. The company continues to promote these products in 2026.”

Significant events

• “Overall turnover from operations increased in the year by 12.2% to £39.702m from £35.371m because of growth in Oxygen and Sleep services. Operating profit increased to £3.402m from £2.326m, which was primarily driven by the successful onboarding of a new Sleep Service contract and the realisation of enhanced operational efficiencies.”
• “The biggest risk is the dependency of the business on three large home oxygen service contracts with the NHS, and one with the NSS - this however is considered low as current NHS contracts were renewed in 2020 for a further 10 years, and the contract with NSS was successfully retendered for a further ten years.”
• “The directors expect the company to continue generating positive cash flows for the foreseeable future, supported by the successful 5-year extensions of three 10-year NHS England service contracts in October 2025. Furthermore, the company's growth was bolstered by the award of a new sleep service contract in 2025, with a subsequent contract launched in February 2026.”
• “Dolby Medical Home Respiratory Care Limited, trading as Vivisol has successfully maintained its Carbon Neutral company certification for the fifth consecutive year.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.